Log In
Print
BCIQ
Print
Print this Print this
 

THxID BRAF test

  Manage Alerts
Collapse Summary General Information
Company bioMerieux S.A.
DescriptionGenetic test to determine BRAF V600E or V600K mutation
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect BRAF V600E or V600K mutation in melanoma patients
Regulatory Designation

Partner

GlaxoSmithKline plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today